江苏景行医药科技

Jiangsu Jingxing Pharmaceutical Technology is a clinical-stage biotechnology company focused on developing innovative small molecule drugs for central nervous system (CNS) disorders. Based in Suzhou, China, the company prioritizes high-unmet-need areas such as treatment-resistant depression and neurodegenerative diseases. Its lead asset, JX-001, is a novel fast-acting antidepressant currently in Phase 2 clinical development. The company was founded by experienced industry veterans with a focus on leveraging advanced medicinal chemistry to create differentiated CNS therapies. Jingxing Pharma's pipeline also includes early-stage programs targeting Parkinson's disease and other psychiatric conditions. The company is backed by prominent venture capital firms including Oriza Holdings and Northern Light Venture Capital.